Yesterday, cancer diagnostics company Pacific Edge Ltd (ASX: PEB) reported a net loss after tax of $35.8 million, up 19.5% on FY25, and operating revenue down 47.4% to $11.5 million for the year ended 31 March 2026.

What did Pacific Edge report?

• Operating revenue: $11.5 million, down 47.4% from FY25
• Net loss after tax: $35.8 million, up 19.5% year on year
• Commercial test volumes: 18,783, down 23.8% on FY25
• Cash burn (2H FY26): $2.4 million per month, down 27.7% on 1H FY26
• APAC operations contributed $2.0 million in FY26 and moved closer to profitability on a direct cost basis
• Post-balance date $36.1 million capital raising completed

What else do investors need to know?

Pacific Edge’s FY26 was a year of strategic delivery, with the company advancing key regulatory and commercial milestones despite the impact of Medicare non-coverage in the US market. Notably, in May 2026, Medicare contractor Novitas published a draft Local Coverage Determination proposing coverage for Cxbladder Triage and Triage Plus—marking a “company-defining milestone”.

In the US, commercial payers covering 10.5 million lives have already adopted medical policy for Pacific Edge’s tests, and operating efficiency improved via reduced cash burn. In the Asia Pacific, the company continues to grow, achieving a 25% lift in average revenue per test after repricing, and APAC operations are now edging toward profitability.

What did Pacific Edge management say?

Chairman Simon Flood said:

Our work is incomplete in this regard, but the draft LCD is a huge step forward and a hard-won recognition for the years of work put in by our Team led by Pete Meintjes. The LCD remains draft, and disciplined execution remains essential as we await confirmation of a final LCD which we hope to receive before the end of this year. The difference that the draft LCD makes is that it gives Pacific Edge a clearer reimbursement pathway and a legitimacy that confirms Cxbladder as the leader in its field, and that’s a great place for us to start rebuilding sales momentum.

What’s next for Pacific Edge?

Management expects the final Medicare coverage decision for Cxbladder Triage and Triage Plus by the end of 2026, which is anticipated to drive higher test volumes and improved unit economics. The company will focus on shifting its US customer base to higher-margin Triage Plus orders, strengthening commercial payer policy, and expanding in APAC and other international markets as regulatory pathways are secured.

Pacific Edge’s ongoing clinical trials and product pipeline are expected to further build clinical evidence and unlock new opportunities. Looking ahead, emphasis remains on disciplined cost control, commercial execution, and innovation to convert its strong position into sustainable profitability and growth.

Pacific Edge share price snapshot

Over the past 12 months, Pacific Edge shares have risen 91%, significantly outperforming the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post Pacific Edge FY26: Loss widens but Medicare draft boost lifts outlook appeared first on The Motley Fool Australia.

More reading

• I think this is one of the best ASX dividend shares to own for the next 10 years
• ClearView Wealth provides update on Zurich acquisition and ASX delisting
• What is Morgan’s view on these ASX 300 shares following earnings results?
• Genesis Minerals FY26 earnings: profit, growth, maiden dividend
• Buy, hold, sell: Bega Cheese, Temple & Webster and Whitehaven Coal shares after results

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The ASX dividend share APA Group (ASX: APA) could be one of the best ideas for passive income in the S&P/ASX 200 Index (ASX: XJO).

APA describes itself as a leading energy infrastructure business. It operates a portfolio of more than $20 billion of assets. This includes gas transmission, processing, compression, and storage assets, with 15,000km of owned gas pipelines being the key asset. It also owns wind farms, solar farms, battery storage, and electricity assets.

Impressively, the business delivers around half of the country’s gas usage, so it’s an integral player in the Australian economy.

With its important assets and growing cash flow, I think it has a great future for the next 10 years and beyond.

Pleasing FY26 result

APA reported a solid set of numbers in the 2026 financial year report.

Total statutory revenue, excluding pass-through revenue, grew 1.9% to $2.76 billion.

The ASX dividend share’s underlying operating profit (EBITDA) climbed 8.3% to $2.18 billion, beating the mid-point of its guidance. There were contributions from newly commissioned assets, inflation-linked tariff escalations, and business-wide cost reduction efforts.

Free cash flow grew 3.2% to $1.1 billion, driven by strong operating cash flow, despite higher tax and interest costs.

APA noted $546 million of capital investment in growth projects, including the Brigalow Peaking Power Plant and pipeline, its East Coast gas grid expansion, and the Sturt Plateau pipeline.

The ASX dividend stock said its organic growth development pipeline has increased to $3.5 billion, up from $3 billion. There’s capacity to fund the investments from the existing balance sheet and the distribution reinvestment plan (DRP).

APA also said it’s progressing a number of attractive long-term growth opportunities, including Beetaloo gas transmission pipelines, contracted gas-powered generation, remote grid power generation, and integrated energy solutions to support the data centre industry. It’s going through the process to advance these plans.

Pleasingly, the business provided underlying EBITDA guidance for FY27 of between $2.26 billion and $2.34 billion, representing year-over-year growth at the mid-point of 5.4%.

That guidance is supported by inflation-linked tariff escalations, a contribution from the new Sturt Plateau pipeline, the conversion of Basslink to a regulated asset, and the annualised benefit of cost reductions.

Why the ASX dividend share is so appealing

The business has provided guidance that it will increase its FY27 distribution to 59 cents per security, which balances rewarding investors with its funding requirements for the organic growth pipeline and the need to maintain its investment-grade credit rating.

With that potential distribution, it would provide a distribution yield of 5.8% at the time of writing.

Impressively, the business increased its annual distribution for the 22nd consecutive year in FY26, which is the second-longest dividend growth streak on the ASX. I think consistency and reliability are extremely important as an ASX dividend share.

In my view, this is one of the best ASX dividend shares to own for the long term. Energy is always needed, and domestically produced energy could become even more important in the years ahead.

The post I think this is one of the best ASX dividend shares to own for the next 10 years appeared first on The Motley Fool Australia.

More reading

• Buy, sell, hold: Dexus, APA, Zip shares
• APA Group FY26 delivers strong earnings, pipeline expansion, and 22nd annual dividend increase
• How much do I need in my superannuation to earn $50,000 per year in passive income?
• How to build a strong ASX retirement portfolio with 10 shares
• ASX 200 utilities shares gained 7% while the broader market fell heavily last week

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Apa Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Yesterday, ClearView Wealth Ltd (ASX: CVW) announced its acquisition by Zurich has been completed, with shareholders receiving $0.60 per share in cash plus a fully franked $0.05 special dividend.

What did ClearView Wealth Limited report?

• Zurich Financial Services Australia Limited has acquired 100% of ClearView shares under the Scheme of Arrangement.
• Shareholders received $0.60 in cash per share and a $0.05 fully franked special dividend per share.
• The Scheme was approved by shareholders on 27 July 2026 and by the Supreme Court of NSW on 30 July 2026.
• ClearView’s shares were suspended from ASX trading on 31 July 2026 and will be delisted on 21 August 2026.
• The ATO has provided a draft Class Ruling relating to the taxation of the scheme and special dividend.

What else do investors need to know?

The acquisition means all ClearView shares are now owned by Zurich, and trading in ClearView shares has ceased. Shareholders on the record date should have received their scheme consideration and special dividend payments.

ClearView has applied for removal from the ASX, which will take effect on 21 August 2026. The company notes that the Australian Tax Office has issued a draft Class Ruling regarding the income tax implication of the scheme and the special dividend. Investors are urged to consult their tax advisers about how these outcomes affect their own circumstances.

What’s next for ClearView Wealth?

With the acquisition now finalised, ClearView will no longer be listed on the ASX and will operate as part of Zurich’s Australian business. Investors are advised to refer to Zurich for future company and strategy updates.

The final Class Ruling from the ATO will be available on the ATO’s website in due course. Shareholders are encouraged to watch for this update, particularly in relation to potential franking credit entitlements.

View Original Announcement

The post ClearView Wealth provides update on Zurich acquisition and ASX delisting appeared first on The Motley Fool Australia.

More reading

• Pacific Edge FY26: Loss widens but Medicare draft boost lifts outlook
• I think this is one of the best ASX dividend shares to own for the next 10 years
• What is Morgan’s view on these ASX 300 shares following earnings results?
• Genesis Minerals FY26 earnings: profit, growth, maiden dividend
• Buy, hold, sell: Bega Cheese, Temple & Webster and Whitehaven Coal shares after results

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.